Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 5/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28469664 | 0.94 | HCRTR2 (0.38) | HCRTR2SIGMAR1SLC18A3KDM4EIDO1 | |
| SCHEMBL11590148 | 0.90 | SLC18A3 (0.41) | HCRTR2SIGMAR1SLC18A3KDM4EIDO1 | |
| SCHEMBL19380876 | 0.90 | SLC18A3 (0.41) | HCRTR2SIGMAR1SLC18A3KDM4EIDO1 | |
| SCHEMBL11619194 | 0.83 | DRD2 (0.46) | HCRTR2KDM4EDRD2 | |
| SCHEMBL10620191 | 0.83 | HCRTR2 (0.37) | HCRTR2SIGMAR1SLC18A3IDO1GRIN2B | |
| SCHEMBL10620204 | 0.83 | HCRTR2 (0.37) | HCRTR2SIGMAR1SLC18A3IDO1GRIN2B | |
| SCHEMBL8558032 | 0.82 | DRD2 (0.45) | HCRTR2KDM4EDRD2TP53CYP3A4 | |
| SCHEMBL11587652 | 0.82 | HCRTR2 (0.38) | HCRTR2SIGMAR1SLC18A3IDO1GRIN2B | |
| SCHEMBL10621649 | 0.80 | HCRTR2 (0.37) | HCRTR2SIGMAR1SLC18A3IDO1MEN1 | |
| SCHEMBL10622372 | 0.80 | HCRTR2 (0.37) | HCRTR2SIGMAR1SLC18A3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| US-4077962-A | WATER INSOLUBLE, GREEN-YELLOW, SYNTHETIC FIBERS | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | HCRTR2 2176/4885SIGMAR1 3910/4885SLC18A3 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.